CA2353616A1 - Assays for compounds which increase phospholipase a2 activity - Google Patents

Assays for compounds which increase phospholipase a2 activity Download PDF

Info

Publication number
CA2353616A1
CA2353616A1 CA002353616A CA2353616A CA2353616A1 CA 2353616 A1 CA2353616 A1 CA 2353616A1 CA 002353616 A CA002353616 A CA 002353616A CA 2353616 A CA2353616 A CA 2353616A CA 2353616 A1 CA2353616 A1 CA 2353616A1
Authority
CA
Canada
Prior art keywords
compound
phospholipase
docosahexaenoic acid
expression
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002353616A
Other languages
English (en)
French (fr)
Inventor
David John Heal
Keith Frank Martin
Kevin Stuart John Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2353616A1 publication Critical patent/CA2353616A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
CA002353616A 1998-12-08 1999-12-07 Assays for compounds which increase phospholipase a2 activity Abandoned CA2353616A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9826899.8A GB9826899D0 (en) 1998-12-08 1998-12-08 Methods to treat depression and other psychiatric disorders and assays for compounds
GB9826899.8 1998-12-08
PCT/EP1999/009546 WO2000034791A1 (en) 1998-12-08 1999-12-07 Assays for compounds which increase phospholipase a2 activity

Publications (1)

Publication Number Publication Date
CA2353616A1 true CA2353616A1 (en) 2000-06-15

Family

ID=10843783

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002353616A Abandoned CA2353616A1 (en) 1998-12-08 1999-12-07 Assays for compounds which increase phospholipase a2 activity

Country Status (6)

Country Link
EP (1) EP1137949A1 (ja)
JP (1) JP2002532687A (ja)
AU (1) AU1971200A (ja)
CA (1) CA2353616A1 (ja)
GB (1) GB9826899D0 (ja)
WO (1) WO2000034791A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001703D0 (en) * 2000-01-25 2000-03-15 Glaxo Group Ltd Assay
KR20030046896A (ko) * 2001-12-07 2003-06-18 학교법인 포항공과대학교 당질코르티코이드에 의해 발현이 조절되는 재조합 리포터유전자를 가지는 형질전환 세포주 및 이를 이용한당질코르티코이드 유사물질 및 저해물질의 생물학적검색방법
WO2003071271A1 (fr) * 2002-02-21 2003-08-28 Tokyo Gas Company Limited Agents de tests pour evaluer l'effet pharmacologique de medicaments, et procede et reactifs pour selectionner des medicaments ayant un excellent effet d'administration et/ou peu d'effets secondaires parmi des medicaments avec enzymes, inhibiteurs d'enzymes ou ligands de recepteurs et/ou promedicaments de ceux-ci
CN104777314B (zh) * 2009-08-12 2017-01-04 福满代谢组技术有限公司 抑郁症的生物标记物、抑郁症的生物标记物的测定方法、计算机程序及记录介质

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US5464754A (en) * 1993-08-17 1995-11-07 The Regents Of The University Of California Assay and substrate for arachidonoyl-specific phospholipase A2

Also Published As

Publication number Publication date
WO2000034791A1 (en) 2000-06-15
EP1137949A1 (en) 2001-10-04
AU1971200A (en) 2000-06-26
JP2002532687A (ja) 2002-10-02
GB9826899D0 (en) 1999-01-27

Similar Documents

Publication Publication Date Title
Dunphy et al. Signalling functions of protein palmitoylation
Kansanen et al. Regulation of Nrf2-dependent gene expression by 15-deoxy-Δ12, 14-prostaglandin J2
Fang et al. Dexras1: AG protein specifically coupled to neuronal nitric oxide synthase via CAPON
Milosevic et al. Plasmalemmal phosphatidylinositol-4, 5-bisphosphate level regulates the releasable vesicle pool size in chromaffin cells
Kim et al. 1, 25‐Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA‐binding, co‐activator recruitment, and histone acetylation in intact osteoblasts
Monkawa et al. Identification of 25-hydroxyvitamin D3 1α-hydroxylase gene expression in macrophages
US7803557B2 (en) Methods for identification of eicosapentaenoic acid analogs using anti-inflammatory receptors
EP3721227B1 (en) Olfactory receptor involved in the perception of musk fragrance and the use thereof
Minuz et al. Lipid peroxidation, isoprostanes and vascular damage
Charpentier et al. Potent and selective peptide-based inhibition of the G protein Gαq
Maraldi et al. Laminopathies: a chromatin affair
CA2353616A1 (en) Assays for compounds which increase phospholipase a2 activity
US7129073B2 (en) Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
Shioda Dopamine D2L receptor-interacting proteins regulate dopaminergic signaling
Giguère et al. ARF6 activation by Gαq signaling: Gαq forms molecular complexes with ARNO and ARF6
Qiao et al. The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPα isoform in transfected COS-7 cells
Meijer et al. Arachidonic acid metabolism in starfish oocytes
AU2002316279A1 (en) Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
MXPA01005662A (en) Assays for compounds which increase phospholipase a2 activity
Nagy et al. Platelet inhibitory receptors
MXPA01013424A (es) Clasificacion para compuestos que modulan la fuga protonica de las mitocondrias.
Székely et al. Nutrition and immune system: certain fatty acids differently modify membrane composition and consequently kinetics of KV1. 3 channels of human peripheral lymphocytes
AU2007204864A1 (en) TRPM2-specific inhibitors
Wray NMDA Receptor Independent, Astrocytic Antidepressant Actions of Ketamine
EP2097753B1 (en) Allosteric modulation of ship polypeptides and uses thereof

Legal Events

Date Code Title Description
FZDE Dead